Tenaya Therapeutics, Inc.
TNYA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001858848
In the last 90 days, Tenaya Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 101 institutions reported holding it in 13F filings for Q2 2026, worth $39.7M in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in Tenaya Therapeutics, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 98
- +10 vs. Q3 2025
- Shares held
- 68.6M
- +34.1M (+98.7%) vs. Q3 2025
- Total value
- $48.8M
- −$6.74M (−12.1%) vs. Q3 2025
- New holders
- 28
- 30 more added
- Sold out
- 18
- 20 more reduced
3 institutions that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TNYA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 101 | $39.7M |
| Q1 2026 | 103 | $37.5M |
| Q4 2025 | 98 | $48.8M |
| Q3 2025 | 91 | $55.6M |
| Q2 2025 | 89 | $19.3M |
| Q1 2025 | 107 | $27.7M |
| Q4 2024 | 88 | $62.8M |
| Q3 2024 | 95 | $111.2M |
| Q2 2024 | 96 | $177.0M |
| Q1 2024 | 90 | $292.9M |
| Q4 2023 | 74 | $151.4M |
| Q3 2023 | 77 | $126.8M |
| Q2 2023 | 79 | $279.7M |
| Q1 2023 | 65 | $128.3M |
| Q4 2022 | 68 | $94.7M |
| Q3 2022 | 73 | $102.2M |
| Q2 2022 | 50 | $208.6M |
| Q1 2022 | 50 | $439.9M |
| Q4 2021 | 47 | $667.6M |
| Q3 2021 | 47 | $693.4M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Tenaya Therapeutics, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Diadema Partners LP | 0 | $0 | 0.00% | −315,519−100.0% | Sold out |
| Trustees of Columbia University in the City of New York | 0 | $0 | 0.00% | −291,828−100.0% | Sold out |
| Persistent Asset Partners Ltd | 0 | $0 | 0.00% | −72,494−100.0% | Sold out |
| Quadrature Capital Ltd | 0 | $0 | 0.00% | −49,024−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −36,253−100.0% | Sold out |
| Independent Financial Group, LLC | 0 | $0 | 0.00% | −25,000−100.0% | Sold out |
| Commonwealth Equity Services, LLC | 0 | $0 | 0.00% | −24,950−100.0% | Sold out |
| Ieq Capital, LLC | 0 | $0 | 0.00% | −23,686−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −19,995−100.0% | Sold out |
| Scientech Research LLC | 0 | $0 | 0.00% | −16,414−100.0% | Sold out |
| Peregrine Asset Advisers, Inc. | 0 | $0 | 0.00% | −12,370−100.0% | Sold out |
| Cambridge Investment Research Advisors, Inc. | 0 | $0 | 0.00% | −12,186−100.0% | Sold out |
| Ameritas Advisory Services, LLC | 0 | $0 | 0.00% | −5,000−100.0% | Sold out |
| Evergreen Private Wealth LLC | 0 | $0 | 0.00% | −1,263−100.0% | Sold out |
| Essential Partners LLC | 0 | $0 | 0.00% | −480−100.0% | Sold out |
| SRS Capital Advisors, Inc. | 0 | $0 | 0.00% | −60−100.0% | Sold out |
| Point72 Asia (Singapore) Pte. Ltd. | – | – | – | – | Not filed |
| Cubist Systematic Strategies, LLC | – | – | – | – | Not filed |
| Point72 (DIFC) Ltd | – | – | – | – | Not filed |